Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Journal Information
Full Title: Ann Hematol
Abbreviation: Ann Hematol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Conflicts of interest Author APSF declares that she has no conflict of interest. Author FSS that she has no conflict of interest. Author ARNA has received a speaker honorarium from Novartis, Brazil. Author FMS that she has no conflict of interest. Author FVRM that he has no conflict of interest. LN that she has no conflict of interest. RRG that he has no conflict of interest. ARLR that he has no conflict of interest. MPSF that he has no conflict of interest. EMR that he has no conflict of interest. VR that he has no conflict of interest. IB that he has no conflict of interest."
Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025